Aon PLC/ IE00BLP1HW54 /
2024-05-24 9:59:55 PM | Chg. +1.41 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
280.79USD | +0.50% | 94,666 Turnover: 26.55 mill. |
-Bid Size: - | -Ask Size: - | 126.08 bill.USD | 0.86% | 22.28 |
GlobeNewswire
05-15
American Oncology Network Advances Karyogram Segmentation and Increases the Speed to Results with Ne...
GlobeNewswire
05-14
American Oncology Network Announces Date Change for First Quarter 2024 Earnings Release Date and Con...
GlobeNewswire
05-14
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
GlobeNewswire
05-08
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 ...
GlobeNewswire
04-30
American Oncology Network Announces First Quarter 2024 Earnings Release Date and Conference Call
GlobeNewswire
04-25
American Oncology Cares Foundation Expands Non-Medical Financial Support to Local Cancer Patients in...
GlobeNewswire
04-24
Savvy Security Establishes Executive Advisory Board Amid Significant First-Year Growth
GlobeNewswire
04-22
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland...
GlobeNewswire
04-22
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland...
GlobeNewswire
04-11
The Joint Commission Enterprise Announces Four Appointments to Executive Leadership Team
GlobeNewswire
04-11
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent ...
GlobeNewswire
04-10
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as Pr...
GlobeNewswire
04-08
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammatio...